Progyny (NASDAQ:PGNY) Price Target Raised to $38.00

Progyny (NASDAQ:PGNY) had its price objective upped by analysts at Citizens Jmp from $33.00 to $38.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s price objective suggests a potential upside of 10.95% from the company’s current price.

Several other research firms have also recently issued reports on PGNY. Leerink Partners set a $38.00 price objective on shares of Progyny in a research report on Wednesday, July 22nd. KeyCorp boosted their target price on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Barclays dropped their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 12th. Wells Fargo & Company restated an “overweight” rating and set a $38.00 price target on shares of Progyny in a report on Thursday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Progyny in a research report on Thursday. Ten investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus target price of $34.92.

Progyny Price Performance

Shares of Progyny stock opened at $34.25 on Thursday. The stock’s 50 day simple moving average is $27.11 and its 200-day simple moving average is $24.49. The stock has a market cap of $2.63 billion, a P/E ratio of 37.01, a P/E/G ratio of 2.01 and a beta of 0.97. Progyny has a 1-year low of $16.10 and a 1-year high of $34.90.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. The firm had revenue of $341.25 million for the quarter, compared to the consensus estimate of $340.76 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 earnings per share. As a group, research analysts expect that Progyny will post 1.25 EPS for the current fiscal year.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares of the company’s stock, valued at $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Melissa B. Cummings sold 1,879 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total transaction of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This trade represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 17,282 shares of company stock worth $475,790. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Leuthold Group LLC purchased a new position in Progyny in the 3rd quarter valued at approximately $322,000. Oregon Public Employees Retirement Fund increased its position in shares of Progyny by 4.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock worth $435,000 after acquiring an additional 700 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Progyny in the third quarter valued at $278,000. Summit Global Investments acquired a new stake in shares of Progyny in the third quarter valued at $1,105,000. Finally, State of Wyoming raised its stake in shares of Progyny by 3.5% in the third quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after acquiring an additional 1,015 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported Q3 earnings of $0.52 per share, above analyst estimates, on revenue of $341.25 million, slightly ahead of expectations and up 8.9% year over year. The company also characterized the quarter as record-setting. Progyny Q3 results
• Positive Sentiment: The company raised its full-year 2026 earnings guidance and issued fourth-quarter guidance. A higher forecast can signal improving expectations for profitability. 2026 earnings guidance
• Positive Sentiment: Citizens raised its price target to $38 following the guidance increase, while Cantor Fitzgerald lifted its target from $31 to $35 and maintained an Overweight rating. Citizens price-target update
• Neutral Sentiment: A Q3 review highlighted new client wins and margin expansion, but described the market response as cautious—suggesting investors may want further evidence that growth and profitability will persist. Q3 business and market review

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.